FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceuticals and can be used for treating folate receptor-negative cancer. The method for treating folate receptor-negative cancer includes administration of a therapeutically effective amount of one or more compounds including a ligand binding to a folate receptor attached to a medicinal product through a linker, wherein the suppressor cells of myeloid origin are inhibited or depleted, and wherein the ligand binding to the folate receptor constitutes folate, to the host animal. The group of inventions also relates to variants of said method and to a method for targeting suppressor cells of myeloid origin.
EFFECT: group of inventions provides effective treatment of folate receptor-negative cancer by targeting suppressor cells of myeloid origin.
45 cl, 37 dwg, 2 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TOLL-LIKE RECEPTOR 7 OR 8 AGONIST AND CHOLESTEROL COMPLEX AND ITS USE | 2020 |
|
RU2790702C1 |
| COMBINED METHODS OF THERAPY FOR TREATMENT OF CANCEROUS TUMORS | 2017 |
|
RU2747258C2 |
| CONJUGATES OF LIGAND AND DRUGS | 2006 |
|
RU2470668C2 |
| IMMUNE-MODIFYING PARTICLES FOR CANCER TREATMENT | 2019 |
|
RU2794261C2 |
| CONJUGATES, CONTAINING HYDROPHILIC SPACERS OF LINKERS | 2008 |
|
RU2523909C2 |
| POLY-LIGAND MEDICINAL CONJUGATES AND USE THEREOF | 2016 |
|
RU2722449C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| DRUG BILIGAND CONJUGATE AND USE THEREOF | 2020 |
|
RU2820346C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| ANTICANCER THERAPY USING COMPOUNDS OF 3,5-DISUBSTITUTED BENZENE ALKYNYL AND PEMBROLIZUMAB | 2020 |
|
RU2822064C2 |
